The vaccine uses self-amplifying RNA, which replicates itself following administration and is thus effective at extremely low doses. In addition, it is stable at refrigerator temperatures--unlike current mRNA vaccines, which require ultra-cold storage.
With TODAY's action by Indian regulators, Gemcovac becomes the first saRNA vaccine ever approved for human use.
HDT Bio's vaccine is currently undergoing clinical trials in the US, Brazil, and South Korea.
HDT Bio is a biopharmaceutical company dedicated to providing immunotherapies to people around the world, including those in historically underserved areas.
The company seeks to harness the body's immune system to deliver therapies that narrowly target the specific areas of the body where they are needed. HDT Bio's work focuses on oncological and infectious disease applications.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer